Trials / Recruiting
RecruitingNCT07171034
A Phase I Study of KLA318-2 Nanocrystal Injection
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KLA318-2 Nanocrystal Injection in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Hunan Kelun Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KLA318-2 Nanocrystal Injection | Intravenous injection, single dose |
| DRUG | Celebrex Capsule | P.O., single dose |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
- First posted
- 2025-09-12
- Last updated
- 2025-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07171034. Inclusion in this directory is not an endorsement.